Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

ReNeuron Signs Agreement with Welsh Government to Lease Facility

Published: Wednesday, April 16, 2014
Last Updated: Wednesday, April 16, 2014
Bookmark and Share
Agreement to lease a new R&D, manufacturing and headquarters facility in South Wales.

ReNeuron Group has announced that it has signed an agreement with the Welsh Government to lease a landmark building at Pencoed Technology Park, near Cardiff, South Wales.

A key element of ReNeuron’s £33 million funding in 2013 was support from the Welsh Government and the Welsh Life Sciences Fund, allied to the relocation of the business to a new facility in South Wales. This move will bring together ReNeuron’s world-class research and development activities, GMP cell manufacture and allied corporate functions in one location, providing operational synergies as the Company’s therapeutic candidates move through clinical development to future market approval. The Company envisages the creation of up to 70 further jobs to be based at the site as cell manufacturing comes on-stream and builds over the next two years and beyond.

ReNeuron plans to commence the relocation of its operations to this site in April 2015, when the conversion of the existing building is expected to be complete. The ground floor of this facility will provide the Company with more than 25,000 square feet of research and development laboratories, GMP clean rooms designed for automated cell culture, and office accommodation, with scope to expand further if required in the future. When licensed for GMP cell manufacture, the facility will provide for ReNeuron’s late-stage clinical and initial commercial product requirements, from 2016 onwards.

The cost of converting and fitting out the building will be borne by the Welsh Government as part of the above-mentioned financial support package.

Edwina Hart MBE, Minister for Economy, Science and Transport in the Welsh Government, said: “I am delighted that plans are now well underway for ReNeuron’s relocation to Wales. Life sciences is one of our priority economic sectors and regenerative medicine is fast becoming an emerging sub-sector for Wales thanks to the presence of some world-class researchers. We have ambitious plans to grow this sector and build on our existing strengths. Attracting a company of the calibre of ReNeuron is central to this strategy. Their pioneering work is renowned internationally and the decision to move to Wales has created interest around the world.”

Michael Hunt, Chief Executive Officer of ReNeuron, said: “We are delighted to have signed an agreement to lease this landmark building in South Wales, which marks a further significant step in ReNeuron’s business development strategy. When complete, we believe the building will house the UK’s most advanced commercial cell therapy manufacturing facility and we are delighted to continue to work with the Welsh Government to bring this important project to fruition. Taking full control of the manufacture of our cell-based therapies is a key value driver for our business, reducing risk and enabling considerable future cost savings through manufacturing efficiencies and downstream economies of scale. Combined with the recent success we have achieved in developing off-the-shelf cryopreserved cell therapy candidates, we believe we are at the forefront in creating a commercially viable cell therapy business.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,100+ scientific posters on ePosters
  • More Than 4,500+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

ReNeuron Receives US Patent on Cell Cryopreservation Technology
ReNeuron Group is pleased to announce that it has received a Notice of Allowance from the US Patent and Trademark Office for a key patent application covering its cell cryopreservation technology.
Wednesday, February 03, 2016
ReNeuron Wins Major UK Grant
ReNeuron Group, a leading UK-based stem cell therapy development company, is pleased to announce that it has been awarded a £2.1 million grant from Innovate UK to further advance its emerging exosome nanomedicine platform.
Thursday, January 14, 2016
FDA Approves Start of Phase I/II Clinical Trial in the US
Company has received regulatory approval in the US with its hRPC therapy candidate for retinitis pigmentosa.
Tuesday, May 05, 2015
ReNeuron Provides Corporate Update
The Company believes reconfiguring the Board and expanding the executive leadership will take them through to full commercialisation.
Wednesday, April 23, 2014
ReNeuron Comments on EU Legal Opinion on Patenting of Human Embryonic Stem Cells
A legal opinion has been given by the advocate-general of the ECJ regarding a patent test case originally brought in Germany and ultimately referred to the ECJ.
Tuesday, May 03, 2011
A Progress Update on ReN009 Stem Cell Therapy for Peripheral Arterial Disease
The Reneuron Group have provided an update on the progress of its ReN009 stem cell therapy for peripheral arterial disease.
Wednesday, November 17, 2010
ReNeuron Receives Final Regulatory Approval to Commence Landmark Stroke Clinical Trial in UK
The approval represents the final national regulatory step in taking the ReN001 therapy into patients in the UK.
Monday, February 15, 2010
ReNeuron Signs Manufacturing Contract to Provide Stem Cells for Stroke Clinical Trial
ReNeuron Group announced that it has signed a contract with Angel Biotechnology Holdings, under which Angel will manufacture clinical-grade ReN001 stem cell lots for ReNeuron's Phase I clinical trial with its ReN001 therapy in disabled stroke patients.
Tuesday, June 09, 2009
ReNeuron Announces Filing IND Application to the FDA for ReN001
ReNeuron files IND application to commence human clinical studies with ReN001 stem cell therapy for stroke.
Friday, December 08, 2006
ReNeuron Demonstrates Key Characteristics with its Hepatocyte Cell Lines
These cell lines have been shown to express a range of adult human liver functional markers.
Monday, October 31, 2005
Scientific News
The Rise of 3D Cell Culture and in vitro Model Systems for Drug Discovery and Toxicology
An overview of the current technology and the challenges and benefits over 2D cell culture models plus some of the latest advances relating to human health research.
New NIH-EPA Research Centers to Study Environmental Health Disparities
Scientists will partner with community organizations to study these concerns and develop culturally appropriate ways to reduce exposure to harmful environmental conditions.
Structure of Essential Digestive Enzyme Uncovered
Using a powerful combination of techniques from biophysics to mathematics, researchers have revealed new insights into the mechanism of a liver enzyme that is critical for human health.
Air Pollution Linked to Heart Disease
10-year project revealed air pollutants accelerate plaque build-up in arteries to the heart.
Getting a Better Look at How HIV Infects and Takes Over its Host Cells
A new approach, developed by a team of researchers led by The Rockefeller University and The Aaron Diamond AIDS Research Center (ADARC), offers an unprecedented view of how a virus infects and appropriates a host cell, step by step.
Following Tricky Triclosan
Antibacterial product flows through streams, crops.
Vitamin A May Help Improve Pancreatic Cancer Chemotherapy
The addition of high doses of a form of vitamin A could help make chemotherapy more successful in treating pancreatic cancer, according to an early study by Queen Mary University of London (QMUL).
Poverty Marks a Gene, Predicting Depression
New study of high-risk teens reveals a biological pathway for depression.
World’s Largest Coral Gene Database
‘Genetic toolkit’ will help shed light on which species survive climate change.
A Boost for Regenerative Medicine
Growing tissues and organs in the lab for transplantation into patients could become easier after scientists discovered an effective way to produce three-dimensional networks of blood vessels, vital for tissue survival yet a current stumbling block in regenerative medicine.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,100+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,500+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!